- Home
- MNRO vs GHRS Comparison
MNRO vs GHRS Comparison
Compare MNRO & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNRO
- GHRS
- Stock Information
- Founded
- MNRO 1957
- GHRS 2018
- Country
- MNRO United States
- GHRS Ireland
- Employees
- MNRO N/A
- GHRS N/A
- Industry
- MNRO Automotive Aftermarket
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- MNRO Consumer Discretionary
- GHRS Health Care
- Exchange
- MNRO Nasdaq
- GHRS Nasdaq
- Market Cap
- MNRO 658.9M
- GHRS 583.1M
- IPO Year
- MNRO 1991
- GHRS 2021
- Fundamental
- Price
- MNRO $12.22
- GHRS $10.60
- Analyst Decision
- MNRO Buy
- GHRS Strong Buy
- Analyst Count
- MNRO 4
- GHRS 8
- Target Price
- MNRO $20.75
- GHRS $30.63
- AVG Volume (30 Days)
- MNRO 686.1K
- GHRS 146.4K
- Earning Date
- MNRO 05-22-2025
- GHRS 05-08-2025
- Dividend Yield
- MNRO 9.12%
- GHRS N/A
- EPS Growth
- MNRO N/A
- GHRS N/A
- EPS
- MNRO 0.62
- GHRS N/A
- Revenue
- MNRO $1,210,419,000.00
- GHRS N/A
- Revenue This Year
- MNRO N/A
- GHRS N/A
- Revenue Next Year
- MNRO $2.89
- GHRS N/A
- P/E Ratio
- MNRO $19.91
- GHRS N/A
- Revenue Growth
- MNRO N/A
- GHRS N/A
- 52 Week Low
- MNRO $13.50
- GHRS $6.00
- 52 Week High
- MNRO $31.49
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- MNRO 26.08
- GHRS 59.36
- Support Level
- MNRO $13.53
- GHRS $9.81
- Resistance Level
- MNRO $14.40
- GHRS $11.50
- Average True Range (ATR)
- MNRO 0.53
- GHRS 0.72
- MACD
- MNRO -0.10
- GHRS 0.23
- Stochastic Oscillator
- MNRO 0.85
- GHRS 89.60
About MNRO Monro Inc.
Monro Inc is a provider automobile service stations in the United States. Through its network of company-owned service stations, Monro Muffler Brake offers maintenance, repair, tire, and fleet management services for automobiles focused largely on undercar services such as brake, steering, exhaust, drivetrain, and suspension systems. Next to service stores, the company also offers tire stores specialised in tire replacement and service.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.